Board MeetingAug 6, 2026, 08:05 AM
Madrigal to Present at Canaccord Genuity Growth Conference on Aug 11
AI Summary
Madrigal Pharmaceuticals announced its participation in the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, at 12:00 P.M. EDT. The presentation will be available via live webcast and replay. The company is a biopharmaceutical firm focused on MASH, with its drug Rezdiffra approved by the FDA and European Commission for MASH with moderate to advanced fibrosis.
Key Highlights
- Madrigal Pharmaceuticals will participate in the Canaccord Genuity 46th Annual Growth Conference.
- The presentation is scheduled for Tuesday, August 11, 2026, at 12:00 P.M. EDT.
- A live webcast of the presentation will be available, with a replay offered afterward.
- Madrigal Pharmaceuticals focuses on developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).
- Its medication, Rezdiffra, is a once-daily, oral, liver-directed THR-β agonist.
- Rezdiffra is approved by the FDA and European Commission for MASH with moderate to advanced fibrosis.
- An ongoing Phase 3 trial is evaluating Rezdiffra for compensated MASH cirrhosis.
Price Impact
More from MDGL